MRI for DES
This article was originally published in The Gray Sheet
Executive SummaryFDA clears labeling for drug-eluting stents allowing a magnetic resonance imaging exam immediately following implant. The agency approved the claim for Boston Scientific's Taxus paclitaxel-eluting stent and J&J/Cordis' Cypher sirolimus-eluting stent on April 5 and April 20, respectively, based on lab studies. Previously, DES labeling advised waiting two months before an MRI exam for fear that the magnetism would cause the stent to heat or migrate...
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.